Ahmed Abdalbagi: Aspirin vs Plavix – Updated Clinical and Pharmacological Breakdown
Ahmed Abdalbagi, SCFHS-Licensed Pharmacist, shared a post on LinkedIn:
“Aspirin vs. Plavix: Updated clinical and pharmacological breakdown:
Drug class and mechanism:
- Aspirin (acetylsalicylic acid):
Irreversible cox-1 inhibitor |Antiplatelet + NSAID (anti-inflammatory, analgesic, antipyretic). - Plavix (clopidogrel):
Irreversible P2Y12 ADP-receptor inhibitor | Pure antiplatelet – NO NSAID effects. - Available strengths:
Aspirin: 75mg, 81mg, 100mg, 300mg (varies by indication). Plavix: 75mg (maintenance), 300mg (loading dose).
Key contraindications:
Aspirin: Active peptic ulcer, NSAID-sensitive asthma, bleeding disorders, severe renal/hepatic impairment.
Plavix: Active bleeding, intracranial hemorrhage, hypersensitivity – safe in asthma.
Shared contraindication:
ITP (immune thrombocytopenia) – high bleeding risk.
Critical drug interaction alert – updated guidelines:
Plavix + PPIs: Significant interaction via CYP2C19 inhibition – reduces clopidogrel antiplatelet efficacy.
Avoid: Omeprazole, Esomeprazole.
Preferred PPI if mandatory: Pantoprazole (minimal CYP2C19 effect).
2024 recommendation: Use H2 blockers (e.g., famotidine) or PPI only if strongly indicated.
Primary indications – secondary prevention:
Acute Coronary Syndrome (ACS), MI, Ischemic Stroke, Post-PCI/Stent, Post-CABG.
DAPT (Dual Antiplatelet Therapy): Aspirin + Clopidogrel – duration individualized per bleeding/thrombosis risk.
DAPT Duration Post-PCI: Short-term (3-6 months) for high bleeding risk; extended if high thrombotic risk.
Genetic testing: CYP2C19 loss-of-function alleles – consider for clopidogrel non-responders.
Primary prevention: Aspirin reserved for select high CV risk patients (no routine use).
For all healthcare professionals:
Guidelines align with ACC/AHA and ESC – emphasize personalized antiplatelet therapy.
Hospital and community pharmacists: Screen for ppi interactions, educate on adherence, monitor bleeding signs.
Are you updating your DAPT protocols based on latest guidelines? How do you manage PPI interactions in practice? Tag a colleague who needs to see this.”
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 4, 2026, 08:27Daniel Pereira Monteiro: HbF Raised with HbC and HbA – What to Do Next?
-
Apr 4, 2026, 08:13Eoin McGrath: Common Language for Blood Transfer Across Organizations
-
Apr 3, 2026, 17:59A Free Hemoglobin Screening Camp for Kaikadi Vasti and Eramushti Community Women – Hope Foundation Sironcha
-
Apr 3, 2026, 17:53Carlos Henrique Del Carlo: HFpEF and Iron Deficiency – Why Treating the Mitochondrial Engine Matters More Than We Thought?
-
Apr 3, 2026, 17:46Michelle Leona Cecil: A Call to Protect Patient Care and The Nation’s Blood Supply for Blood Disorders Community
-
Apr 3, 2026, 17:38Shahab Sheikhalishahi: A Rare Case of Portal Vein Thrombosis After Echis Carinatus Envenomation
-
Apr 3, 2026, 17:33Kimberly Ha: Epia Neuro Aims to Restore Movement in Stroke Survivors
-
Apr 3, 2026, 17:28Ryan Perry: Heart and Stroke Announces 2026 Grants-in-Aid Indigenous Research Stream Funding Opportunity
-
Apr 3, 2026, 17:21Maxime Dely: A Meaningful Journey of 14 years in Blood Transfusion